<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274612</url>
  </required_header>
  <id_info>
    <org_study_id>502.391</org_study_id>
    <nct_id>NCT00274612</nct_id>
  </id_info>
  <brief_title>Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM</brief_title>
  <acronym>PRISMA</acronym>
  <official_title>A Prospective Randomised Open- Label Blinded-Endpoint (PROBE) Trial Comparing Telmisartan (MICARDIS®) (40-80-80mg QD) and Ramipril (2.5-5--10mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. PRISMA = Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate that telmisartan 80 mg (MICARDIS®) is&#xD;
      at least as effective and possibly superior to ramipril 5mg and 10mg in lowering mean&#xD;
      ambulatory diastolic blood pressure (DBP) and systolic blood pressure (SBP) during the last 6&#xD;
      hours of the 24-hour dosing interval in mild-to-moderate hypertensive patients at the end of&#xD;
      an 8 and 14-week treatment period, respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives will compare telmisartan (80 mg) (MICARDIS® and ramipril (5 mg and 10&#xD;
      mg) on: 1) the reduction in the last 6-hour ABPM mean pulse pressure (PP) relative to dosing,&#xD;
      2) the reductions in the 24-hour ABPM mean DBP, SBP and PP relative to dosing, 3) reductions&#xD;
      in ABPM mean DBP, SBP and PP during other periods of the 24-hour dosing interval (i.e.,&#xD;
      morning, daytime, and nighttime) relative to clock time, 4) change from baseline in systolic&#xD;
      and diastolic blood pressure load during the 24-hour dosing interval, 5) reductions in the&#xD;
      mean seated trough DBP and SBP measured using a manual in-clinic cuff sphygmomanometer, 6)&#xD;
      responder rates as determined by both ABPM and manual in-clinic cuff measurements and 7)&#xD;
      Health-Related Quality of Life (HRQL).&#xD;
&#xD;
      Study Hypothesis:&#xD;
&#xD;
      It is hypothesised that the rise of blood pressure (BP) during the last hours of the sleeping&#xD;
      period is a cause of the high incidence of cardiovascular events in the morning. The purpose&#xD;
      of the present study is to demonstrate that telmisartan (MICARDIS®) is not inferior to&#xD;
      ramipril in lowering blood pressure in patients with mild-to-moderate hypertension. Blood&#xD;
      pressure will be assessed by ambulatory blood pressure monitoring (ABPM) as this will allow&#xD;
      comparison of the full 24-hour effects of both treatments without artefacts (e.g., white-coat&#xD;
      hypertension) introduced by measurement of blood pressure in the clinic. This will measure&#xD;
      diastolic blood pressures over the entire 24-hour dosing interval, with primary attention&#xD;
      focused on the last six hours of the dosing interval.&#xD;
&#xD;
      NULL AND ALTERNATIVE HYPOTHESES In order to test the multiple hypotheses (e.g.,&#xD;
      non-inferiority and superiority of telmisartan compared to ramipril), multiple dosages (i.e.,&#xD;
      telmisartan 80mg (MICARDIS®) versus ramipril 5mg and ramipril 10mg after 8 and 14 weeks of&#xD;
      treatment, respectively), and the two endpoints (i.e., reduction in DBP and SBP during the&#xD;
      last 6 hours of the 24-hour dosing interval) as measured by ABPM, a completely hierarchical,&#xD;
      closed testing procedure will be used.&#xD;
&#xD;
      Hierarchical Closed Testing Procedure:&#xD;
&#xD;
        1. Non-inferiority of telmisartan 80 mg (MICARDIS®) compared to ramipril 5 mg at the end of&#xD;
           the 8 week treatment period in the reduction of DBP during the last 6 hours of the 24&#xD;
           hour dosing interval; if significant then,&#xD;
&#xD;
        2. Superiority of telmisartan 80 mg (MICARDIS®) compared to ramipril 5 mg at the end of the&#xD;
           8-week treatment period in the reduction of DBP during the last 6 hours of the 24-hour&#xD;
           dosing interval; if significant then,&#xD;
&#xD;
        3. Superiority of telmisartan 80mg (MICARDIS®) compared to ramipril 5 mg at the end of the&#xD;
           8-week treatment period in the reduction of SBP during the last 6 hours of the 24-hour&#xD;
           dosing interval; if significant then,&#xD;
&#xD;
        4. Non-inferiority of telmisartan 80mg (MICARDIS®) compared to ramipril 10 mg at the end of&#xD;
           an 14 week treatment period in the reduction of DBP during the last 6 hours of the&#xD;
           24-hour dosing interval; if significant then,&#xD;
&#xD;
        5. Superiority of telmisartan 80mg (MICARDIS®) compared to ramipril 10 mg at the end of an&#xD;
           14-week treatment period in the reduction of DBP during the last 6 hours of the 24-hour&#xD;
           dosing interval; and if significant then,&#xD;
&#xD;
        6. Superiority of telmisartan 80mg (MICARDIS®) compared to ramipril 10mg at the end of an&#xD;
           14-week treatment period in the reduction of SBP during the last 6 hours of the 24-hour&#xD;
           dosing interval.&#xD;
&#xD;
      A difference of 2 mmHg was determined to be the maximum difference between the mean&#xD;
      reductions in DBP during the last 6 hours of the 24-hour dosing interval for the two&#xD;
      treatments which would be considered to have no clinical importance (i.e., the limit for non&#xD;
      inferiority). Thus non-inferiority of telmisartan compared to ramipril will be tested using&#xD;
      the following set of hypotheses:&#xD;
&#xD;
      Null Hypothesis:&#xD;
&#xD;
      The overall mean reduction from baseline in ABPM mean DBP during the last 6 hours of the&#xD;
      24-hour dosing interval for telmisartan 80 mg (MICARDIS®) is inferior to that for ramipril by&#xD;
      at least 2 mmHg.&#xD;
&#xD;
      Alternative Hypothesis: The overall mean reduction from baseline in ABPM mean DBP during the&#xD;
      last 6 hours of the 24-hour dosing interval for telmisartan 80mg (MICARDIS®) is less than 2&#xD;
      mmHg smaller than that for ramipril.&#xD;
&#xD;
      These hypotheses can be stated as:&#xD;
&#xD;
      H0: dT - dR less than or equal to -2 mmHg versus HA: dT - dR &gt; -2 mmHg where dT and dR&#xD;
      represent the overall mean reduction from baseline in ABPM mean DBP during the last 6 hours&#xD;
      of the 24-hour dosing interval for telmisartan and ramipril, respectively, adjusted for any&#xD;
      other factors included in the statistical model.&#xD;
&#xD;
      If the lower limit of the two-sided 95% confidence interval for the difference between the&#xD;
      least square means of both treatments (telmisartan - ramipril) lies above -2 mmHg, then it&#xD;
      will be concluded that telmisartan 80mg (MICARDIS®) is at least as effective as ramipril (5mg&#xD;
      after 8 weeks of treatment or 10mg after 14 weeks of treatment, depending upon the&#xD;
      comparison) in reducing DBP during the last 6 hours of the 24-hour dosing interval.&#xD;
&#xD;
      Superiority of telmisartan (MICARDIS®) compared to ramipril will be tested using the&#xD;
      following set of hypotheses:&#xD;
&#xD;
      Null Hypothesis:&#xD;
&#xD;
      The overall mean reduction from baseline in the ABPM mean during the last 6 hours of the&#xD;
      24-hour dosing interval for telmisartan 80mg (MICARDIS®) is less than or equal to that for&#xD;
      ramipril.&#xD;
&#xD;
      Alternative Hypothesis: The overall mean reduction from baseline in the ABPM mean during the&#xD;
      last 6 hours of the 24-hour dosing interval for telmisartan 80mg (MICARDIS®) is greater than&#xD;
      that for ramipril.&#xD;
&#xD;
      These hypotheses can be stated as:&#xD;
&#xD;
      H0: dT - dR less than or equal to 0 mmHg versus HA: dT - dR &gt; 0 mmHg where dT and dR&#xD;
      represent the overall mean reduction from baseline in ABPM mean DBP during the last 6 hours&#xD;
      of the 24-hour dosing interval for telmisartan and ramipril, respectively, adjusted for any&#xD;
      other factors included in the statistical model.&#xD;
&#xD;
      If the lower limit of the two-sided 95% confidence interval for the difference between the&#xD;
      least square means of both treatments (telmisartan (MICARDIS®) - ramipril) is greater than&#xD;
      zero, then it will be concluded that telmisartan 80mg (MICARDIS®) is statistically superior&#xD;
      to ramipril (5mg after 8 weeks of treatment or 10mg after 14 weeks of treatment, depending&#xD;
      upon the comparison) in reducing blood pressure (DBP or SBP, depending upon the comparison)&#xD;
      during the last 6 hours of the 24-hour dosing interval.&#xD;
&#xD;
      Comparison(s):&#xD;
&#xD;
      Reductions in blood pressure during the last 6 hours of the 24-hour dosing interval as&#xD;
      measured by ABPM in patients treated with telmisartan (MICARDIS®) compared to patients&#xD;
      treated with ramipril. The primary analysis will consist of a closed testing procedure first&#xD;
      testing for non-inferiority of telmisartan 80mg (MICARDIS®) compared to ramipril 10mg after&#xD;
      fourteen weeks of treatment in the reduction in diastolic blood pressure (DBP); if&#xD;
      significant, testing for superiority of telmisartan 80 mg (MICARDIS®) compared to ramipril 10&#xD;
      mg in the reduction in DBP; if significant, testing for superiority of telmisartan 80 mg&#xD;
      (MICARDIS®) compared to ramipril 10 mg in the reduction of systolic blood pressure (SBP); if&#xD;
      significant, testing for non-inferiority of telmisartan 80 mg (MICARDIS®) compared to&#xD;
      ramipril 5 mg after eight weeks of treatment in the reduction in DBP; if significant, testing&#xD;
      for superiority of telmisartan 80 mg (MICARDIS®) compared to ramipril 5 mg in the reduction&#xD;
      in DBP; and if significant, testing for superiority of telmisartan 80mg (MICARDIS®) compared&#xD;
      to ramipril 5mg in the reduction in SBP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date>November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the last 6-hour mean (relative to dose time) diastolic and systolic blood pressure (DBP and SBP) as measured by ABPM</measure>
    <time_frame>after 8 and 14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the last 6-hour ABPM mean (relative to dosing time) for pulse pressure (PP)</measure>
    <time_frame>after 8 and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the 24-hour ABPM mean (relative to dosing time) for DBP, SBP and PP</measure>
    <time_frame>after 8 and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the ABPM mean (relative to clock-time) for DBP, SBP and PP during the morning, daytime and night-time periods of the 24-hour dosing interval.</measure>
    <time_frame>after 8 and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in SBP and DBP load during the 24-hour dosing interval</measure>
    <time_frame>after 8 and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mean seated trough DBP and SBP as measured by manual in-clinic cuff sphygmomanometer</measure>
    <time_frame>after 8 and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rates based on both the 24-hour ABPM mean (relative to dose time) BPs and manual in-clinic trough cuff measurements</measure>
    <time_frame>after 8 and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in patient Health Related Quality of Life (HRQL) as measured by Psychological General Wellbeing Index (PGWB).</measure>
    <time_frame>week 8 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manually triggered BP measurements before going to bed and upon arising in the morning</measure>
    <time_frame>after 8 and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 14 weeks</time_frame>
  </secondary_outcome>
  <enrollment>801</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of&#xD;
             greater than or equal to 95 mmHg and less than or equal to 109 mmHg, measured by&#xD;
             manual cuff sphygmomanometer at Visit 2.&#xD;
&#xD;
          2. 24-hour mean DBP of greater than or equal to 85 mmHg at Visit 3 as measured by ABPM.&#xD;
&#xD;
          3. Age 18 years or older.&#xD;
&#xD;
          4. Ability to stop any current antihypertensive therapy without risk to the patient&#xD;
             (investigator's discretion).&#xD;
&#xD;
          5. Ability to provide written informed consent in accordance with GCP and local&#xD;
             legislation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-menopausal women (last menstruation approximately less than or equal to 1 year&#xD;
             prior to signing informed consent) who:&#xD;
&#xD;
               -  Are not surgically sterile&#xD;
&#xD;
               -  Are nursing,&#xD;
&#xD;
               -  Are of child-bearing potential and are NOT practicing acceptable methods of birth&#xD;
                  control, or do NOT plan to continue practicing an acceptable method throughout&#xD;
                  the study. Acceptable methods of birth control include intra uterine device,&#xD;
                  oral, implantable or injectable contraceptives.&#xD;
&#xD;
          2. Night shift workers who routinely sleep during the daytime and whose work hours&#xD;
             include midnight to 4:00 A.M.&#xD;
&#xD;
          3. Mean sitting SBP greater than or equal to180 mmHg or mean sitting DBP greater than or&#xD;
             equal to 110 mmHg during any visit of the placebo run-in period.&#xD;
&#xD;
          4. Known or suspected secondary hypertension (i.e., pheochromocytoma).&#xD;
&#xD;
          5. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:&#xD;
&#xD;
               -  SGPT (ALT) or SGOT (AST) &gt; 2 times the upper limit of normal range.&#xD;
&#xD;
               -  Serum creatinine &gt; 2.3mg/dL (or &gt; 203 micromol/l).&#xD;
&#xD;
          6. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney,&#xD;
             post-renal transplant patients or patients with only one kidney.&#xD;
&#xD;
          7. Clinically relevant sodium depletion, hypokalaemia or hyperkalaemia.&#xD;
&#xD;
          8. Uncorrected volume depletion.&#xD;
&#xD;
          9. Primary aldosteronism.&#xD;
&#xD;
         10. Hereditary fructose intolerance.&#xD;
&#xD;
         11. Biliary obstructive disorders.&#xD;
&#xD;
         12. Congestive heart failure (NYHA functional class CHF III-IV).&#xD;
&#xD;
         13. Unstable angina within the past three months prior to start of run in period.&#xD;
&#xD;
         14. Stroke within the past six months prior to start of run in period.&#xD;
&#xD;
         15. Myocardial infarction or cardiac surgery within the past three months prior to start&#xD;
             of run in period.&#xD;
&#xD;
         16. PTCA (percutaneous transluminal coronary angioplasty) within the past three months&#xD;
             prior to start of run in period.&#xD;
&#xD;
         17. Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other&#xD;
             clinically relevant cardiac arrhythmias as determined by the investigator.&#xD;
&#xD;
         18. Hypertrophic obstructive cardiomyopathy, aortic stenosis, haemodynamically relevant&#xD;
             stenosis of the aortic or mitral valve.&#xD;
&#xD;
         19. Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable&#xD;
             and controlled for at least the past three months as defined by an HbA1C greater than&#xD;
             or equal to 10%.&#xD;
&#xD;
         20. Patients who have previously experienced symptoms characteristic of angioedema during&#xD;
             treatment with ACE inhibitors or angiotensin II receptor antagonists.&#xD;
&#xD;
         21. History of drug or alcohol dependency within 6 months prior to start of run in period.&#xD;
&#xD;
         22. Concomitant administration of any medications known to affect blood pressure, except&#xD;
             medication allowed by the protocol.&#xD;
&#xD;
         23. Any investigational therapy within one month of start of run in period.&#xD;
&#xD;
         24. Known hypersensitivity to any component of the formulations.&#xD;
&#xD;
         25. Any clinical condition which, in the opinion of the investigator would not allow safe&#xD;
             completion of the protocol and safe administration of trial medication.&#xD;
&#xD;
         26. Inability to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim Ltd./Bracknell</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rehabilitationszentrum für Herz- und Kreislauferkrankungen</name>
      <address>
        <city>Bad Tatzmannsdorf</city>
        <zip>7431</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. Landeskrankenhaus Bruck a. d. Mur</name>
      <address>
        <city>Bruck a. d. Mur</city>
        <zip>8600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Graz West</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Villach</name>
      <address>
        <city>Villach</city>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.-Klinik für Innere Medizin III</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint André</name>
      <address>
        <city>Bordeaux cedex</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mayenne</city>
        <zip>53100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Laurent du Medoc</city>
        <zip>33112</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saumur</city>
        <zip>49400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaggenau</city>
        <zip>76571</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haag</city>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linkenheim-Hochstetten</city>
        <zip>76351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mühldorf am Inn</city>
        <zip>84453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plattling</city>
        <zip>94447</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterschneidheim</city>
        <zip>73485</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilsbiburg</city>
        <zip>84137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westerkappeln</city>
        <zip>49492</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bennebroek</city>
        <zip>2121 BB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6415 HT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijverdal</city>
        <zip>7441 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3082 DC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <zip>7531</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Emporium</name>
      <address>
        <city>Midrand</city>
        <zip>1685</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vanderbijlpark</city>
        <zip>1911</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1 Military Hospital</name>
      <address>
        <city>Vootrekkehoogte</city>
        <zip>0143</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Galdakao / Vizcaya</city>
        <zip>48680</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pabellon de Consultas</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edificio de Consultas Externas</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Diagnostico y Tratamiento</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pabellon B / 1 piso</name>
      <address>
        <city>Sta Coloma de Gramanet</city>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Basel</city>
        <zip>4055</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schweizerisches Herz- und Gefässzentrum</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiocentro Ticino</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muralto</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ashford</city>
        <zip>TW15 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atherstone</city>
        <zip>CV9 1EU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bath</city>
        <zip>BA2 3HAT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bedworth</city>
        <zip>CV6 4DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV7 8LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Doncaster</city>
        <zip>DN1 2EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fowey</city>
        <zip>PL23 1DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frome</city>
        <zip>BA11 2QE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G69 7AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ilford</city>
        <zip>IG3 8BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leamington Spa</city>
        <zip>CV32 4RA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lesley</city>
        <zip>KY6 3LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lostwithiel</city>
        <zip>PL22 0EF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ryde</city>
        <zip>PO33 2PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trowbridge</city>
        <zip>BA14 7EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wells Next to the Sea</city>
        <zip>NR23 1JP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Whitstable</city>
        <zip>CT5 1BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Whitstable</city>
        <zip>CT5 3QU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York District Hospital</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.391.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.391_literature.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2006</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

